Bispecific Antibodies

Bispecific Antibodies Partner

Bispecific antibodies offer therapeutic mechanisms that go beyond conventional monoclonal antibodies. That engineered, laboratory-made proteins simultaneously bind to two different targets or two distinct epitopes on a single target. By acting as a molecular bridge, they enable novel therapeutic mechanisms. One arm binds to a specific protein on a tumor cell, while the other binds to a receptor (like CD3) on a T-cell, forcing the T-cell to attack the cancer.

The development of bispecific antibodies requires rigorous control of structure, physicochemical and biological parameters. Mabion’s platform combines integrated upstream and downstream process design, modality-relevant analytical development, and quality-by-design principles to support robust and scalable bispecific antibody manufacturing. With scientific and technological excellence, agility, compliance, and partnership-focused execution, Mabion provides a reliable European CDMO environment for bispecific antibody projects that demand both innovation and manufacturing discipline.